Coave Logo.png
Coave Therapeutics to Present at Upcoming Conferences
September 28, 2023 08:15 ET | Coave Therapeutics
Paris, France, September 28, 2023 – Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies for CNS (Central Nervous System) and eye diseases, announces...
Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
September 28, 2023 01:30 ET | Spexis AG
Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
patient summit 2023 invite
Foundation for Sarcoidosis Research announces largest Global Sarcoidosis Virtual Summit – Find Your Community, Find Your Life
September 26, 2023 09:15 ET | Foundation for Sarcoidosis Research
Foundation for Sarcoidosis Research to Host Largest Virtual Sarcoidosis Educational Event of the Year
Walgreens Alabama Campaign pr image
Foundation for Sarcoidosis Research partners with 95 Walgreens stores in Alabama to raise awareness of sarcoidosis and the importance of all impacted by heart and lung disease to get vaccinated
September 15, 2023 15:23 ET | Foundation for Sarcoidosis Research
CHICAGO, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Beginning September 16th, Walgreens, a pharmacy and retail leader who plays a critical role in the U.S. healthcare system by providing a wide range of...
Foundation for Sarcoidosis Research Graduates Second Class of New Volunteers from 11 States to Raise Awareness and Improve Clinical Outcomes for Those Living with Sarcoidosis
September 12, 2023 10:42 ET | Foundation for Sarcoidosis Research
CHICAGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Foundation for Sarcoidosis Research (FSR), the leading international nonprofit organization dedicated to finding a cure and improving care for sarcoidosis...
AlgoTx Announces First Patients Dosed in US and European Arms of Phase II Clinical Trial of ATX01 in Rare Disease Erythromelalgia
September 12, 2023 03:00 ET | AlgoTX
PARIS, Sept. 12, 2023 (GLOBE NEWSWIRE) --  AlgoTherapeutix (AlgoTx), a clinical stage biotechnology company developing targeted, first-in-class therapeutics for peripheral neuropathic pain,...
Parion Corporate Logo-01.png
Parion Sciences Announces Publication of Phase 2 CLEAN-PCD Study in The Lancet Respiratory Medicine
September 08, 2023 09:00 ET | Parion Sciences
Published Phase 2 Study findings demonstrate safety and efficacy of idrevloride in hypertonic saline for treatment of primary ciliary dyskinesiaAbstract to be presented at 2023 European Respiratory...
Zur Behandlung der h
Zur Behandlung der homozygoten familiären Hypercholesterinämie (HoFH): Ultragenyx führt Evkeeza® (Evinacumab) in Deutschland ein
September 01, 2023 02:00 ET | Ultragenyx Pharmaceutical Inc.
BERLIN, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung neuer Therapien für seltene genetische...
Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder
- Presentations Convey Novel Approach for Improving Diagnostic Accuracy and Tracking Disease Severity in MSA - - Data Presented at the International Congress of Parkinson’s Disease and Movement...
Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson’s and Alzheimer’s
MELBOURNE, Australia and SAN FRANCISCO, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...